248 Thyrotropin-α failed to detect localized

tumor recurrence in 7% of patients compared to 100% detection after hormone

withdrawal but detected 100% of patients with metastatic disease.

29,248

J.R. should be maintained on his current L-thyroxine suppression dosage because

his TSH level is appropriately suppressed without hyperthyroidism.

KEY REFERENCES AND WEBSITES

A full list of references for this chapter can be found at

http://thepoint.lww.com/AT11e. Below are the key references and websites for this

chapter, with the corresponding reference number in this chapter found in parentheses

after the reference.

Key References

Bach-Huynh TG et al. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin

Endocrinol Metab. 2009;94:3905. (122)

Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management

guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr

Pract. 2011;17(3):456–520. (34)

Biondi B, Cooper DS. Benefits of thyrotropin suppression versus the risks of adverse effects in differentiated

thyroid cancer. Thyroid. 2010;20:135. (247)

p. 1069

p. 1070

Biondi B, Cooper DS. The clinicalsignificance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76. (88)

Brent GA. Clinical practice: Graves’ disease. N EnglJ Med. 2008;358: 2594. (164)

Cohen-Lehman J et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6:34. (57)

Cooper DS. Antithyroid drugs. N EnglJ Med. 2005;352:905. (176)

Cooper et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and

differentiated thyroid cancer [published correction appears in Thyroid. 2010;20:674]. Thyroid. 2009;19:1167. (30)

Flynn RW et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and

fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95:186. (95)

Garber JR, Cobin RH, Gharib H, et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the

American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract.

2012;18(6):988–1028. (35)

Grozinsky-Glasberg S et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for

clinical hypothyroidism: meta-analysis of randomized controlled trials. J Clin Endocrinol Metab. 2006;91:2592.

(82)

Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab.

2009;23:793. (59)

Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American

thyroid association task force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751. (65)

Jonklaas J et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA.

2008;299:769. (83)

Ross DS. Radioiodine therapy for hyperthyroidism. N EnglJ Med. 2011;364:542. (184)

Stagnaro-Green A, Abalovich M, Alexander E, et al. Guidelines of the American Thyroid Association for the

diagnosis and management of thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081–

1125. (107)

Toft A. Which thyroxine? Thyroid. 2005;15:124. (77)

Key Websites

American Thyroid Association. ATA Frequently Asked Questions (FAQS).

http://www.thyroid.org/patients/faqs.html.

American Thyroid Association. ATA Patient Education Web Brochures.

http://www.thyroid.org/patients/brochures.html.

American Thyroid Association. The Professional Community. http://www.thyroid.org/professionals/.

Graves’ Disease Foundation. http://www.ngdf.org/.

National Cancer Institute. Thyroid Cancer. http://www.cancer.gov/cancertopics/types/thyroid.

ThyCa: Thyroid Cancer Survivors’ Association. http://www.thyca.org/.

COMPLETE REFERENCES CHAPTER 52 THYROID

DISORDERS

Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N EnglJ Med.

2001;344:1743.

Marqusee E et al. The effect of droloxifene and estrogen on thyroid function in postmenopausal women. J Clin

Endocrinol Metab. 2000;85:4407.

Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med. 2005;118:706.

Bocchetta A et al. Fifteen-year follow-up of thyroid function in lithium patients. J Endocrinol Invest. 2007;30:363.

Bocchetta A, Loviselli A. Lithium treatment and thyroid abnormalities. Clin Pract Epidemol Ment Health.

2006;2:23.

Carella C et al. Long-term outcome of interferon-induced thyroid autoimmunity and prognostic influence of thyroid

autoantibody pattern at the end of treatment. J Clin Endocrinol Metab. 2001;86:1925.

Dalgard O et al. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association

with either interferon dosage or efficacy of therapy. J Intern Med. 2002;251:400.

deGroot JWB et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther.

2005;78:433.

DesaiJ et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinalstromal tumors. Ann Intern

Med. 2006;145:660.

Golden WM et al. The retinoid receptor agonist bexarotene inhibits thyrotropin secretion in normalsubjects. J Clin

Endocrinol Metab. 2007;92:124.

Krouse RS et al. Thyroid dysfunction in 281 patients with metastatic melanoma or renal carcinoma treated with

interleukin-2 alone. J Immunother Emphasis Tumor Immunol. 1995;18:272.

Kurnik D et al. Complex drug–drug–disease interactions between amiodarone, warfarin, and the thyroid gland.

Medicine. 2004;83:107.

Lazarus JH. Lithium and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23:723–733.

Lodish MB, Stratakis CA. Endocrine side effects of broad-acting kinase inhibitors. Endocr Relat Cancer.

2010;17(3):R233–R244.

Mandac JC et al. The clinical and physiological spectrum of interferon alpha induced thyroiditis: toward a new

classification. Hepatology. 2006;43:661.

Markou K et al. Iodine-induced hypothyroidism. Thyroid. 2001;11:501.

Martino E et al. The effects of amiodarone on the thyroid. Endocr Rev. 2001;22:240.

McDonnell Me BLE, Bernardo J. Hypothyroidism due to ethionamide. N EnglJ Med. 2005;352:2757.

Rini BI et al. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib. J Natl Cancer

Inst. 2007;99:81.

Smit JW et al. Bexarotene induced hypothyroidism: bexarotene stimulates the peripheral metabolism of thyroid

hormones. J Clin Endocrinol Metab. 2007;92:2496.

Surks MI, Sievert R. Drugs and thyroid function. N EnglJ Med. 1995;333:1688.

Takasu N et al. Rifampin-induced hypothyroidism. J Endocrinol Invest. 2006;29:645.

Weijl NI et al. Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies

and response to treatment. J Clin Oncol. 1993;11:1376.

Wong V et al. Thyrotoxicosis induced by alpha-interferon therapy in chronic viral hepatitis. Clin Endocrinol.

2002;56:793.

Barclay ML et al. Lithium associated thyrotoxicosis: a report of 14 cases, with statistical analysis of incidence.

Clin Endocrinol. 1994;40:759.

Dang AH, Hershman JM. Lithium-associated thyroiditis. Endocrinol Pract. 2002;8:232.

Peeters RP et al. Genetic variation in the thyroid hormone pathway genes; polymorphisms in the TSH receptor

and the iodothyronine deiodinases. Eur J Endocrinol. 2006;155:655.

Roti E, Uberti ED. Iodine excess and hyperthyroidism. Thyroid. 2001;11:493.

The ATAGT. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid.

2006;16:109.

Cooper DS et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules

and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.

Demers LM, Spencer CA. Laboratory Medicine Practice Guidelines. Laboratory support for the diagnosis and

monitoring of thyroid disease. Thyroid. 2003;13:19.

Ross DS. Serum thyroid-stimulating hormone measurement for assessment of thyroid function and disease.

Endocrinol Metab Clin North Am. 2001;30:245.

Surks MI et al. ATA guidelines for use of laboratory tests in thyroid disorders. JAMA. 1990;263:1529.

Bahn RS et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American

Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract. 2011;17(3):456–520.

Garber JR et al. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American

Association of Clinical Endocrinologists and the American Thyroid Association. Endocr Pract. 2012;18(6):988–

1028.

Surks MI et al. The thyrotropin reference range should remain unchanged. J Clin Endocrinol Metab.

2005;90:5489.

deGroot LJ. Non-thyroidal illness syndrome is a manifestation of hypothalamic-pituitary dysfunction, and in view

of current evidence, should be treated with appropriate replacement therapies. Crit Care Clin. 2006;22:57.

Warner MH, Beckett GJ. Mechanisms behind the non-thyroidal illness syndrome, an update. J Endocrinol.

2010;205:1–13.

Plikat K et al. Frequency and outcome of patients with nonthyroidal illness syndrome in a medical intensive care

unit. Metabolism. 2007;56:239.

Slag MF et al. Hypothyroxinemia in critically ill patients as a predictor of high mortality. JAMA. 1981;245:43.

Friberg L et al. Association between increased levels of reverse triiodothyronine and mortality after acute

myocardial infarction. Am J Med. 2001;111:699.

Acker CG et al. Thyroid hormone in the treatment of post-transplant acute tubular necrosis (ATN). Am J

Transplant. 2002;2:57.

Lechan RM. The dilemma of the nonthyroidal illness syndrome. Acta Biomed. 2008;79(3):165–171.

DeGroot LJ. The non-thyroidal illness syndrome. [Updated 2015 Feb 1]. In: De Groot LJ, Beck-Peccoz P,

Chrousos G et al., eds. Endotext. South Dartmouth, MA: MDText.com; 2000.

Wang R et al. Salsalate administration: a potential pharmacological model of the sick euthyroid syndrome. J Clin

Endocrinol Metab. 1998;83:3095.

McDonnell RJ. Abnormal thyroid function test results in patients taking salsalate. JAMA. 1992;267:1242.

Curran PG, Degroot LJ. The effect of hepatic enzyme-inducing drugs on thyroid hormones and the thyroid gland.

Endocrinol Rev. 1991;12:135.

Surks MI, DeFesi CR. Normal serum free thyroid hormone concentrations in patients treated with phenytoin or

carbamazepine: a paradox resolved. JAMA. 1996;275:1495.

Isojarvi JIT et al. Thyroid function in men taking carbamazepine, oxcarbazepine, or valproate for epilepsy.

Epilepsia. 2001;42:930.

Tiihonen M et al. Thyroid status of patients receiving long-term anticonvulsant therapy assessed by peripheral

parameters: a placebo-controlled thyroxine therapy trial. Epilepsia. 1995;36:1118.

Blackshear JL et al. Thyroxine replacement requirements in hypothyroid patients receiving phenytoin. Ann Intern

Med. 1983;99:341.

DeLuca F et al. Changes in thyroid function tests induced by 2 month carbamazepine treatment in L-thyroxinesubstituted hypothyroid children. Eur J Paediatr. 1986;145:77.

English TN et al. Abnormalities in thyroid function associated with chronic therapy with methadone. Clin Chem.

1988;34:2202.

Hsu SHJ et al. Effect of long-term use of raloxifene, a selective estrogen receptor modulatory on thyroid function

test profiles. Clin Chem. 2001;10:1865.

Kostoglour-Athanassiou I et al. Thyroid function in postmenopausal women with breast cancer on tamoxifen. Eur

J Gynaecol Oncol. 1998;19:150.

Eskes SA, Wiersinga WM. Amiodarone and thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):735–751.

Cohen-Lehman J et al. Effects of amiodarone therapy on thyroid function. Nat Rev Endocrinol. 2010;6(1):34–41.

Samuels ER et al. Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in

healthy volunteers. J Psychopharmacol. 2006;20(6):756–770.

Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. Best Pract Res Clin Endocrinol Metab.

2009;23:793–800.

Vigersky RA et al. Thyrotropin suppression by metformin. J Clin Endocrinol Metab. 2006;91:225.

Cappelli C et al. TSH-lowering effect of metformin in type 2 diabetic patients: differences between euthyroid,

untreated hypothyroid, and euthyroid on L-T4 therapy patients. Diabetes Care. 2009;32(9):1589–1590.

Roberts CGP, Ladenson PW. Hypothyroidism. Lancet. 2004;363:793.

Brent GA, Koenig RJ. Chapter 39. Thyroid and Anti-Thyroid Drugs. In: Brunton LL, Chabner BA, Knollmann

BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 12e. New York, NY: The

McGraw-Hill Companies; 2011.

Hoang TD et al. Desiccated thyroid extract compared with levothyroxine in the treatment of hypothyroidism: a

randomized, double-blind, crossover study. J Clin Endocrinol Metab. 2013;98(5):1982–1990.

Jonklaas J et al. Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task

force on thyroid hormone replacement. Thyroid. 2014;24(12):1670–1751.

Sawin CT et al. A comparison of thyroxine and desiccated thyroid in patients with primary hypothyroidism.

Metabolism. 1978;27:1518.

Rees-Jones RW, Larsen PR. Triiodothyronine and thyroxine content of desiccated thyroid tablets. Metabolism.

1977;26:1213.

Rees-Jones RW et al. Hormonal content of thyroid replacement preparations. JAMA. 1980;243:549.

Csako GA et al. Therapeutic potential of two over-the-counter thyroid hormone preparations. Drug Intell Clin

Pharm. 1990;24:26.

Sawin CT, London MH. “Natural” desiccated thyroid, a health food thyroid preparation. Arch Intern Med.

1989;149:2117.

Wiersinga WM. Thyroid hormone replacement therapy. Horm Res. 2001;56(Suppl 1):74.

Fish LH et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of

hypothyroidism. N EnglJ Med. 1987;316:764.

Bolk N et al. The effect of thyroxine is greater when taken at bedtime. Clin Endocrinol (Oxf). 2007;66:43.

Hennessey JV. Levothyroxine a new drug? Since when? How could that be? Thyroid. 2003;13:279.

AACE, TES, and ATA joint position statement on the use and interchangeability of thyroxine products. Thyroid.

2004;14:486.

Blakesley VA. Current methodology to assess bioequivalence of levothyroxine sodium products is inadequate.

AAPS J. 2005;7:E42.

Toft A. Which thyroxine? Thyroid. 2005;15:124.

Gibaldi M. Bioequivalence of thyroid preparations: the final word? AAPS J. 2005;7:E59.

Bolton S. Bioequivalence studies for levothyroxine. AAPS J. 2005;7:E47.

Klein I, Danzi S. Evaluation of the therapeutic efficacy of different levothyroxine preparations in the treatment of

human thyroid disease. Thyroid. 2003;13:1127.

Escobar-Morreale HF et al. Review: treatment of hypothyroidism with combinations of levothyroxine plus

liothyronine. J Clin Endocrinol Metab. 2005;90:4946.

Grozinsky-Glasberg S et al. Thyroxine-triiodothyronine combination therapy versus thyroxine monotherapy for

clinical hypothyroidism: meta-analysis of randomized controlled trials.. J Clin Endocrinol Metab. 2006;91:2592.

Jonklaas J et al. Triiodothyronine levels in athyreotic individuals during levothyroxine therapy. JAMA.

2008;299(7):769–777.

Kaptein EM et al. Clinical review: Thyroid hormone therapy for postoperative nonthyroidal illnesses: a systematic

review and synthesis. J Clin Endocrinol Metab. 2010;95(10):4526–4534.

Fazio S et al. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31.

Murphy E, Williams GR. The thyroid and the skeleton. Clin Endocrinol. 2004;61:285.

Surks MI et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management.

JAMA. 2004;291:228.

Biondi B, Cooper DS. The clinicalsignificance of subclinical thyroid dysfunction. Endocr Rev. 2008;29:76–131.

Mitchell AL, Pearce SHS. How should we treat patients with low serum thyrotropin concentrations? Clin

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

113.

114.

115.

116.

117.

Endocrinol (Oxf). 2010;72:292–296.

Annemieke R et al. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective,

randomized, double-blind trial. Arch Intern Med. 2005;165:1714.

Grund FM, Niewoehner CB. Hyperthyroxinemia in patients receiving thyroid replacement therapy. Arch Intern

Med. 1989;149:921.

Dong BJ et al. Bioequivalence of generic and brand-name levothyroxine products in the treatment of

hypothyroidism. JAMA. 1997;277:1205.

Ain KB et al. Thyroid hormone levels affected by time of blood sampling in thyroxine-treated patients. Thyroid.

1993;3:81.

Walsh JP et al. Small changes in thyroxine dose do not alter well-being or symptoms in patients with

hypothyroidism. J Clin Endocrinol Metab. 2006;91:2624.

Flynn RW et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and

fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010;95(1):186–193.

Sawin CT et al. Aging and the thyroid: decreased requirements for thyroid hormone in older hypothyroid patients.

Am J Med. 1983;75:206.

Davis FB et al. Estimation of a physiologic replacement dose of levothyroxine in elderly patients with

hypothyroidism. Arch Intern Med. 1984;144:1752.

Kabadi UM. Variability of L-thyroxine replacement dose in elderly patients with primary hypothyroidism. J Fam

Pract. 1987;24:473.

Grebe SKG et al. Treatment of hypothyroidism with once-weekly thyroxine. J Clin Endocrinol Metab.

1997;82:870.

Haddow JE et al. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development

of the child. N EnglJ Med. 1999;341:549.

Pop VJ et al. Maternal hypothyroxinemia during early pregnancy and subsequent child development: a 3-year

follow-up study. Clin Endocrinol. 2003;59:282.

Galofre JC, Davies TF. Autoimmune thyroid disease in pregnancy: a review. J Womens Health (Larchmt).

2009;18(11):1847–1856.

Mandel SJ et al. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl

J Med. 1990;323:91.

Alexander EK et al. Timing and magnitude of increases in levothyroxine requirements during pregnancy in

women with hypothyroidism. N EnglJ Med. 2004;351:241.

Abalovich M et al. Management of thyroid dysfunction during pregnancy and postpartum: an Endocrine Society

Clinical Practice Guideline. J Clin Endocrinol Metab. 2007;92(8, Suppl):S1–S47.

Vaidya B et al. Detection of thyroid dysfunction in early pregnancy: universal screening or targeted high-risk

case finding? J Clin Endocrinol Metab. 2007;92:203.

Stagnaro-Green A et al. Guidelines of the American Thyroid Association for the diagnosis and management of

thyroid disease during pregnancy and postpartum. Thyroid. 2011;21(10):1081–1125.

Chopra IJ, Baber K. Treatment of primary hypothyroidism during pregnancy: is there an increase in thyroxine

dose requirement in pregnancy? Metabolism. 2003;52:122.

Rastogi MV, LaFranchi SH. Congenital hypothyroidism. Orphanet J Rare Dis. 2010;5:17.

Rovet JF. In search of the optimal therapy for congenital hypothyroidism. J Pediatr. 2004;144:698.

Salerno M et al. Effect of different starting doses of levothyroxine on growth and intellectual outcome at four

years of age in congenital hypothyroidism. Thyroid. 2002;12:45.

Bongers-Schokking JJ et al. Influence of timing and dose of thyroid hormone replacement on mental,

psychomotor, and behavioral development in children with congenital hypothyroidism. J Pediatr. 2005;147:768.

Rovet JF. Children with congenital hypothyroidism and their siblings: do they really differ? Pediatrics.

2005;115:e52.

Oerbeck B et al. Congenital hypothyroidism: influence of disease severity and L-thyroxine treatment on

intellectual, motor, and school-associated outcomes in young adults. Pediatrics. 2003;112:923.

Simoneau-Roy J et al. Cognition and behavior at school entry in children with congenital hypothyroidism treated

early with high-dose levothyroxine. J Pediatr. 2004;144:747.

Heyerdahl S, Oerbeck B. Congenital hypothyroidism: developmental outcome in relation to levothyroxine

treatment variables. Thyroid. 2003;13:1029.

Oerbeck B et al. Congenital hypothyroidism: no adverse effects of high dose thyroxine treatment on adult

memory, attention, and behavior. Arch Dis Child. 2005;90:132.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

Selva KA et al. Initial treatment dose of L-thyroxine in congenital hypothyroidism. J Pediatr. 2002;141:786.

Ain KB et al. Pseudomalabsorption of levothyroxine. JAMA. 1991;266:2118.

Sherman SI, Malecha SE. Absorption and malabsorption of levothyroxine. Am J Ther. 1995;2:814.

Benvenga S et al. Delayed intestinal absorption of levothyroxine. Thyroid. 1995;5:249.

Bach-Huynh TG et al. Timing of levothyroxine administration affects serum thyrotropin concentration. J Clin

Endocrinol Metab. 2009;94(10):3905–3912.

Liel Y et al. Evidence for a clinically important adverse effect of f iber-enriched diet on the bioavailability of

levothyroxine in adult hypothyroid patients. J Clin Endocrinol Metab. 1996;80:857.

Bell DS, Ovalle F. Use of soy protein supplement and resultant need for increased dose of levothyroxine. Endocr

Pract. 2001;7:193.

Benvenga S et al. Altered intestinal absorption of L-thyroxine caused by coffee. Thyroid. 2008;18(3):293–301.

Siraj ES et al. Raloxifene causing malabsorption of levothyroxine. Arch Intern Med. 2003;163:1367.

Harmon SM, Seifert CF. Levothyroxine-cholestyramine interaction reemphasized [letter]. Ann Intern Med.

1991;115:658.

Campbell NRC et al. Ferrous sulfate reduces thyroxine efficacy in patients with hypothyroidism. Ann Intern

Med. 1992;117:1010.

Demke DM. Drug interaction between thyroxine and lovastatin [letter]. N EnglJ Med. 1989;321:1341.

Sperber AD, Liel Y. Evidence for interference with the intestinal absorption of levothyroxine sodium by

aluminum hydroxide. Arch Intern Med. 1992;152:183.

Havrankova J, Lahaie R. Levothyroxine binding by sucralfate [letter]. Ann Intern Med. 1992;117:445.

Singh N et al. Effect of calcium carbonate on the absorption of levothyroxine. JAMA. 2000;283:2822.

Singh N et al. The acute effect of calcium carbonate on the intestinal absorption of levothyroxine. Thyroid.

2001;11:967.

Diskin CJ et al. Effect of phosphate binders upon TSH and L-thyroxine dose in patients on thyroid replacement.

Int Urol Nephrol. 2007;39:599.

Centanni M et al. Thyroxine absorption is decreased in patients with Helicobacter pylori-related gastritis and

atrophic gastritis and by omeprazole therapy. N EnglJ Med. 2006;354:1787.

Dietrich JW et al. Absorption kinetics of levothyroxine is not altered by proton-pump inhibitor therapy. Horm

Metab Res. 2006;38:57.

Duntas LH. Thyroid disease and lipids. Thyroid. 2002;12:287.

Wartoksky L. Myxedema coma. Endocrinol Metab Clin North Am. 2006;35:687.

Yamamoto T et al. Factors associated with mortality of myxedema coma: report of eight cases and literature

survey. Thyroid. 1999;9:1167.

MacKerrow SD et al. Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. Ann

Intern Med. 1992;117:1014.

Pereira VG et al. Management of myxedema coma: report on three successfully treated cases with nasogastric

or intravenous administration of triiodothyronine. J Endocrinol Invest. 1982;5:331.

Ladenson PW et al. Rapid pituitary and peripheral tissue responses to intravenous L-triiodothyronine in

hypothyroidism. J Clin Endocrinol Metab. 1983;56:1252.

Hylander B, Rosenqvist U. Treatment of myxedema coma: factors associated with fatal outcome. Acta

Endocrinol (Copenh). 1985;108:65.

Ariot S et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine

treatment. Intensive Care Med. 1991;17:16.

Kohno A, Hara Y. Severe myocardial ischemia following hormone replacement in two cases of hypothyroidism

with normal coronary arteriogram. EndocrinolJ. 2001;48:565.

Fadeyev VV et al. Levothyroxine replacement therapy in patients with subclinical hypothyroidism and coronary

artery disease. Endocr Pract. 2006;12:5.

Levine D. Compromise therapy in the patient with angina pectoris and hypothyroidism. Am J Med. 1980;69:411.

Lawrence JR et al. Digoxin kinetics in patients with thyroid dysfunction. Clin Pharmacol Ther. 1977;22:7.

Doherty JE et al. Digoxin metabolism in hypo- and hyperthyroidism. Ann Intern Med. 1966;64:489.

Myerowitz PD. Diagnosis and management of the hypothyroid patient with chest pain. J Thorac Cardiovasc

Surg. 1983;86:57.

Becker C. Hypothyroidism and atherosclerotic heart disease: pathogenesis, medical management and the role of

coronary artery bypass surgery. Endocrinol Rev. 1985;6:432.

Staub HG et al. Prospective study of the spontaneous course of subclinical hypothyroidism: prognostic value of

153.

154.

155.

156.

157.

158.

159.

160.

161.

162.

163.

164.

165.

166.

167.

168.

169.

170.

171.

172.

173.

174.

175.

176.

177.

178.

179.

180.

181.

182.

183.

thyrotropin, thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab. 2002;87:3221.

McDermott MT, Ridgway EC. Subclinical hypothyroidism is mild thyroid failure and should be treated. J Clin

Endocrinol Metab. 2001;86:4585.

Kong WM et al. A 6-month randomized trial of thyroxine treatment in women with mild subclinical

hypothyroidism. Am J Med. 2002;112:348.

Meier C et al. TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinicalsymptoms in subclinical

hypothyroidism: a double blind placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab.

2001;86:4860.

Rodondi N et al. The risk of coronary heart disease is increased in subclinical hypothyroidism. Am J Med.

2006;119:541.

Walsh JP et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med.

2005;165:2467.